Arca
Skip to content
Tools
Tools

HNF4A: Hepatocyte nuclear factor 4-alpha

Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 0

Who is on it, and how far along

Every drug ChEMBL records acting on HNF4A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved0

    Phase 30

      Phase 21

      • Alverine

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        AlverinePhase 2—Small moleculeActivatorHepatocyte nuclear factor 4-alpha activator5

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.
        Carvedilol and Alverine in Portal HypertensionAlverinePhase 2 / Phase 3Not yet recruitingShanghai Changzheng HospitalNov 20, 2024
        Ebastine Versus Mebeverine in IBS PatientsAlverinePhase 3Active, not recruitingGuy BoeckxstaensApr 18, 2023
        The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot StudyAlverinePhase 2Enrolling by invitationShanghai Changzheng HospitalAug 19, 2022
        The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)AlverineNot applicableNot yet recruitingUniversity of PecsOct 29, 2021
        Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel SyndromeAlverinePhase 3RecruitingTanta UniversityJan 3, 2020

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Maturity-onset diabetes of the young0.82
        • Type 2 diabetes mellitus0.80
        • Renal cysts and diabetes syndrome0.74
        • Monogenic diabetes0.68
        • Cholelithiasis0.55
        • Intrahepatic cholestasis of pregnancy0.52
        • Gallstones0.51
        • Cholecystitis0.48
        • Gastrointestinal disease0.46
        • Hyperinsulinism due to HNF4A deficiency0.45

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5398, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P41235, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.